Since the late 1970s I have been active along the international research front studying the major scavenger cells, their receptors, and the metabolic fate of the material that these cells clear from the circulation with remarkable efficiency. During the initial years of my research career, I was employed by academia (University of Oslo, UiT The Arctic University of Norway, University of Michigan, Uppsala University). During my work with my PhD dissertation at Uppsala University I developed by the early 1980s a novel method allowing mass isolation and culture of the two major types of liver scavenger cells from single rats. This allowed for the first time detailed studies on the scavenger activity of the liver sinusoidal endothelial cell (LSEC), which permitted the conclusion that these cells together play a major role in the clearance of an array of large molecules and nano formulations from the circulation. Due to the detailed knowledge that I developed in this field, I was contacted by the pharma industry, who wanted to apply the new findings to establish the mechanism of clearance of various large molecule drug candidates. Later, when the industry started to be interested in the potential of using nano-particles as vectors for various drug candidates, more industries got interested in the understanding and methods that I had developed. Hence, during my career I worked as project partner with KabiVitrum, AstraZeneca, NovoNordisk, to name a few. Moreover, after I started the CRO D’Liver in 2011, an additional number of pharma companies made contact and established collaboration.

A more detailed CV can be found on my LinkedIn profile. Details on my employment history, education and qualifications and publication record are available on my ORCID profile. In addition, bibliometric parameters (number of citation and h-index) of my research publications are available on my Google Scholar profile.